Evidence map›Paper›PMID 27941766›Full record

ArticleBone marrow transplantation2017

Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.

S Terakura, A Wake, Y Inamoto, M Murata, R Sakai, T Yamaguchi, S Takahashi, N Uchida, Y Onishi, K Ohashi and 8 more

Open access · bronzeAbstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

S TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1194-8046
A WakeDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.ORCID http://orcid.org/0000-0002-9653-6170
Y InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
M MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
R SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
T YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
S TakahashiDepartment of Cell Processing and Transfusion, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
N UchidaOkinaka Memorial Institute of Medical Research, Tokyo, Japan.
Y OnishiDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
K OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Y OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
H KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
H YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
T FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
T IchinoheDepartment of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.
M TakanashiBlood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Y AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
T TeshimaDepartment of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Kanagawa Prefectural Hospital Organization · JPNagoya University · JPToranomon Hospital · JPHiroshima University Hospital · JPHokkaido University · JPJapanese Red Cross Society, Japan · JPNippon Medical School · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTohoku University · JPTohoku University Hospital · JPTokyo Medical University Hospital · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to examine GvHD prophylaxis in umbilical cord blood transplantation (UCBT) in more detail, we compared transplant outcomes after UCBT for acute leukemia among GvHD prophylaxes using registry data. We selected patients transplanted with a calcineurin inhibitor and methotrexate (MTX)/mycophenolate mofetil (MMF) combination. A total of 1516 first myeloablative UCBT between 2000 and 2012 (Cyclosporine A (CyA) plus MTX, 824, Tacrolimus (Tac) plus MTX, 554, Tac plus MMF, 138) were included. With adjusted analyses, Tac plus MMF showed a significantly higher risk for grade II-IV and III-IV acute GvHD than CyA or Tac plus MTX. Although NRM was similar, Tac plus MMF showed a significantly lower risk of relapse than CyA or Tac plus MTX. A significant difference was observed in the risk of overall mortality (OM) between the MTX-containing group and MMF-containing group. In patients with standard-risk disease, there was no significant difference in the risk of OM in any GvHD prophylaxis. However, in patients with advanced-risk disease, Tac plus MMF showed a significantly lower risk of OM. Therefore, MTX-containing prophylaxis is preferred in UCBT for standard-risk disease, whereas MMF-containing prophylaxis is preferred for advanced-risk disease. A prospective study to identify optimal GvHD prophylaxis for UCBT is warranted.

Indexed as

Cord Blood Stem Cell TransplantationAdolescentAdultCyclosporineDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansIncidenceJapanLeukemia, Myeloid, AcuteMaleMethotrexateMiddle AgedMycophenolic AcidPrecursor Cell Lymphoblastic Leukemia-LymphomaCyclosporineMethotrexateMycophenolic AcidTacrolimus

Identifiers

PMID27941766
OpenAlexW2560888315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.